Link to Full Article Award to help fund a Phase 1/2 clinical trial of the company’s Pseudomonas aeruginosa phage candidate, AP-PA02, as a treatment for drug-resistant respiratory infections in cystic fibrosis patients Armata to collaborate with the Cystic Fibrosis Therapeutics Development Network MARINA DEL REY, Calif., March 18, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-03-18 02:32:452020-03-19 02:34:27Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation
Link to Full Article Study to enroll a minimum of 65 patients across the United States to evaluate safety and effectiveness of treatment of acute, non-burn skin injuries Valencia, Calif., USA, and Melbourne, Australia, 3, March 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-03-03 03:19:052020-03-17 03:26:57First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
Link to Full Article Phase 2b study on track to complete recruitment in mid-2020 Earlier grant funded programs progressing to plan Company well-funded through to mid-2021 Brighton, United Kingdom – 3 March 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-03-03 02:40:172020-03-19 02:44:48Clinical and Business Update
Link to Full Article Adherium Limited ABN 24 605 352 510 Appendix 4D Interim Consolidated Financial Report for the six months ended 31 December 2019 Adherium Limited (“Adherium”, the “Company” or the “Group”) presents this financial report, including the interim financial statements, for the six months ended 31 December Results for announcement […]
Link to Full Article Arecor formulated biosimilar product progressing through clinical studies Cambridge, UK., 25 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-02-25 02:16:112020-02-28 02:18:16ARECOR ACHIEVES SECOND LICENSE MILESTONE PAYMENT FROM GLOBAL PHARMACEUTICAL PARTNER
Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 19 February 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that it filed today with the Australian Securities Exchange (ASX) its Appendix 4D – Half-Year […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-02-19 02:19:412020-02-28 02:24:01AVITA Medical Half-Year Financial Report for Fiscal 2020
Link to Full Article – Armata withdraws its previously filed registration statement on Form S-1 MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-02-13 02:46:502020-02-14 02:49:01Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.
Link to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-02-13 02:43:022020-02-14 02:45:51ARECOR SIGNS A NEW FEASIBILITY STUDY AGREEMENT WITH TOP FIVE PHARMA COMPANY
Link to Full Article 11 February 2020 – Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has successfully reached its target of $5.4 million raised through its Rights Issue by allocating 17,517,309 shares in entitlement subscriptions and 162,206,104 shortfall shares to wholesale and exempt […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-02-11 03:06:212020-03-17 03:10:52Adherium Raises $5.4 million to Complete Rights Issue and Shortfall Placement
Link to Full Article U.S. RECELL® System product sales of A$4.66M for fiscal second quarter Valencia, Calif., USA, and Melbourne, Australia, 31 January 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-31 02:57:512020-02-04 03:06:47AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update
Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation
/in Armata PharmaceuticalsLink to Full Article Award to help fund a Phase 1/2 clinical trial of the company’s Pseudomonas aeruginosa phage candidate, AP-PA02, as a treatment for drug-resistant respiratory infections in cystic fibrosis patients Armata to collaborate with the Cystic Fibrosis Therapeutics Development Network MARINA DEL REY, Calif., March 18, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) […]
First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
/in Avita MedicalLink to Full Article Study to enroll a minimum of 65 patients across the United States to evaluate safety and effectiveness of treatment of acute, non-burn skin injuries Valencia, Calif., USA, and Melbourne, Australia, 3, March 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to […]
Clinical and Business Update
/in Destiny PharmaLink to Full Article Phase 2b study on track to complete recruitment in mid-2020 Earlier grant funded programs progressing to plan Company well-funded through to mid-2021 Brighton, United Kingdom – 3 March 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address […]
Half Yearly Report and Accounts
/in AdheriumLink to Full Article Adherium Limited ABN 24 605 352 510 Appendix 4D Interim Consolidated Financial Report for the six months ended 31 December 2019 Adherium Limited (“Adherium”, the “Company” or the “Group”) presents this financial report, including the interim financial statements, for the six months ended 31 December Results for announcement […]
ARECOR ACHIEVES SECOND LICENSE MILESTONE PAYMENT FROM GLOBAL PHARMACEUTICAL PARTNER
/in ArecorLink to Full Article Arecor formulated biosimilar product progressing through clinical studies Cambridge, UK., 25 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered […]
AVITA Medical Half-Year Financial Report for Fiscal 2020
/in Avita MedicalLink to Full Article Valencia, Calif., USA, and Melbourne, Australia, 19 February 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that it filed today with the Australian Securities Exchange (ASX) its Appendix 4D – Half-Year […]
Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.
/in Armata PharmaceuticalsLink to Full Article – Armata withdraws its previously filed registration statement on Form S-1 MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently […]
ARECOR SIGNS A NEW FEASIBILITY STUDY AGREEMENT WITH TOP FIVE PHARMA COMPANY
/in ArecorLink to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]
Adherium Raises $5.4 million to Complete Rights Issue and Shortfall Placement
/in AdheriumLink to Full Article 11 February 2020 – Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has successfully reached its target of $5.4 million raised through its Rights Issue by allocating 17,517,309 shares in entitlement subscriptions and 162,206,104 shortfall shares to wholesale and exempt […]
AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update
/in Avita MedicalLink to Full Article U.S. RECELL® System product sales of A$4.66M for fiscal second quarter Valencia, Calif., USA, and Melbourne, Australia, 31 January 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the […]